184 related articles for article (PubMed ID: 29888103)
1. ERBB3, IGF1R, and TGFBR2 expression correlate with PDGFR expression in glioblastoma and participate in PDGFR inhibitor resistance of glioblastoma cells.
Song K; Yuan Y; Lin Y; Wang YX; Zhou J; Gai QJ; Zhang L; Mao M; Yao XX; Qin Y; Lu HM; Zhang X; Cui YH; Bian XW; Zhang X; Wang Y
Am J Cancer Res; 2018; 8(5):792-809. PubMed ID: 29888103
[TBL] [Abstract][Full Text] [Related]
2. Insulin-Mediated Signaling Facilitates Resistance to PDGFR Inhibition in Proneural hPDGFB-Driven Gliomas.
Almiron Bonnin DA; Ran C; Havrda MC; Liu H; Hitoshi Y; Zhang Z; Cheng C; Ung M; Israel MA
Mol Cancer Ther; 2017 Apr; 16(4):705-716. PubMed ID: 28138037
[TBL] [Abstract][Full Text] [Related]
3. ATRX-Deficient High-Grade Glioma Cells Exhibit Increased Sensitivity to RTK and PDGFR Inhibitors.
Pladevall-Morera D; Castejón-Griñán M; Aguilera P; Gaardahl K; Ingham A; Brosnan-Cashman JA; Meeker AK; Lopez-Contreras AJ
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406561
[TBL] [Abstract][Full Text] [Related]
4. EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma.
Gai QJ; Fu Z; He J; Mao M; Yao XX; Qin Y; Lan X; Zhang L; Miao JY; Wang YX; Zhu J; Yang FC; Lu HM; Yan ZX; Chen FL; Shi Y; Ping YF; Cui YH; Zhang X; Liu X; Yao XH; Lv SQ; Bian XW; Wang Y
Signal Transduct Target Ther; 2022 Feb; 7(1):33. PubMed ID: 35105853
[TBL] [Abstract][Full Text] [Related]
5. InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.
Ma Y; Tang N; Thompson RC; Mobley BC; Clark SW; Sarkaria JN; Wang J
Clin Cancer Res; 2016 Apr; 22(7):1767-76. PubMed ID: 26561558
[TBL] [Abstract][Full Text] [Related]
6. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
Lokker NA; Sullivan CM; Hollenbach SJ; Israel MA; Giese NA
Cancer Res; 2002 Jul; 62(13):3729-35. PubMed ID: 12097282
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor 1/insulin-like growth factor 1 receptor signaling protects against cell apoptosis through the PI3K/AKT pathway in glioblastoma cells.
Zhang M; Liu J; Li M; Zhang S; Lu Y; Liang Y; Zhao K; Li Y
Exp Ther Med; 2018 Aug; 16(2):1477-1482. PubMed ID: 30116397
[TBL] [Abstract][Full Text] [Related]
8. PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment.
Cenciarelli C; Marei HE; Zonfrillo M; Pierimarchi P; Paldino E; Casalbore P; Felsani A; Vescovi AL; Maira G; Mangiola A
Mol Cancer; 2014 Nov; 13():247. PubMed ID: 25380967
[TBL] [Abstract][Full Text] [Related]
9. PDGFR-β-activated ACK1-AKT signaling promotes glioma tumorigenesis.
Zhang J; Chen T; Mao Q; Lin J; Jia J; Li S; Xiong W; Lin Y; Liu Z; Liu X; Zhao H; Wang G; Zheng D; Qiu S; Ge J
Int J Cancer; 2015 Apr; 136(8):1769-80. PubMed ID: 25257795
[TBL] [Abstract][Full Text] [Related]
10. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
11. Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter?
Qin A; Musket A; Musich PR; Schweitzer JB; Xie Q
Neurooncol Adv; 2021; 3(1):vdab133. PubMed ID: 34806012
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Han J; Puri RK
J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
[TBL] [Abstract][Full Text] [Related]
13. FRMD6 inhibits human glioblastoma growth and progression by negatively regulating activity of receptor tyrosine kinases.
Xu Y; Wang K; Yu Q
Oncotarget; 2016 Oct; 7(43):70080-70091. PubMed ID: 27661120
[TBL] [Abstract][Full Text] [Related]
14. Sprouty2 Drives Drug Resistance and Proliferation in Glioblastoma.
Walsh AM; Kapoor GS; Buonato JM; Mathew LK; Bi Y; Davuluri RV; Martinez-Lage M; Simon MC; O'Rourke DM; Lazzara MJ
Mol Cancer Res; 2015 Aug; 13(8):1227-37. PubMed ID: 25934697
[TBL] [Abstract][Full Text] [Related]
15. Targeting Aurora kinase B attenuates chemoresistance in glioblastoma via a synergistic manner with temozolomide.
Alafate W; Wang M; Zuo J; Wu W; Sun L; Liu C; Xie W; Wang J
Pathol Res Pract; 2019 Nov; 215(11):152617. PubMed ID: 31563286
[TBL] [Abstract][Full Text] [Related]
16. G-protein coupled receptor kinase (GRK)-5 regulates proliferation of glioblastoma-derived stem cells.
Kaur G; Kim J; Kaur R; Tan I; Bloch O; Sun MZ; Safaee M; Oh MC; Sughrue M; Phillips J; Parsa AT
J Clin Neurosci; 2013 Jul; 20(7):1014-8. PubMed ID: 23693024
[TBL] [Abstract][Full Text] [Related]
17. EGFR and PDGFRA co-expression and heterodimerization in glioblastoma tumor sphere lines.
Chakravarty D; Pedraza AM; Cotari J; Liu AH; Punko D; Kokroo A; Huse JT; Altan-Bonnet G; Brennan CW
Sci Rep; 2017 Aug; 7(1):9043. PubMed ID: 28831081
[TBL] [Abstract][Full Text] [Related]
18. Epithelial membrane protein 3 regulates TGF-β signaling activation in CD44-high glioblastoma.
Jun F; Hong J; Liu Q; Guo Y; Liao Y; Huang J; Wen S; Shen L
Oncotarget; 2017 Feb; 8(9):14343-14358. PubMed ID: 27527869
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of GBP1 predicts poor prognosis and promotes tumor growth in human glioblastoma multiforme.
Ji X; Zhu H; Dai X; Xi Y; Sheng Y; Gao C; Liu H; Xue Y; Liu J; Shi J; Zhang Y; Chen Y; Dai X; Li M; Wang A; Dong J
Cancer Biomark; 2019; 25(3):275-290. PubMed ID: 29991124
[TBL] [Abstract][Full Text] [Related]
20. Underexpression of HOXA11 Is Associated with Treatment Resistance and Poor Prognosis in Glioblastoma.
Se YB; Kim SH; Kim JY; Kim JE; Dho YS; Kim JW; Kim YH; Woo HG; Kim SH; Kang SH; Kim HJ; Kim TM; Lee ST; Choi SH; Park SH; Kim IH; Kim DG; Park CK
Cancer Res Treat; 2017 Apr; 49(2):387-398. PubMed ID: 27456940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
